Financial insights of ASRT

MyFinsight

For the quarter ending 2026-03-31, ASRT made $9,933K in revenue. -$18,856K in net income. Net profit margin of -189.83%.

Income Statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total revenues	9,933	13,544	49,459	29,222
Cost of sales	2,711	3,266	13,654	10,677
Research and development expenses	454	486	379	387
Selling, general and administrative expenses	19,434	13,135	16,930	16,960
Change in fair value of contingent consideration	-	552*	-276	-
Amortization of intangible assets	5,804	5,803	5,594	9,233
Impairment of intangible assets	-	-552*	1,700	-
Restructuring charges	0	2,600	0	0
Total costs and expenses	28,403	25,290	37,981	37,257
Loss from operations	-18,470	-11,746	11,478	-8,035
Gain on assertio therapeutics divestiture	-	-4*	0	-8,174
Interest expense	775	768*	770	768
Interest income	469	606	664	675
Other loss	-35	166	26	6
Total other expense	-341	0	-80	-8,261
Net loss before income taxes	-18,811	-11,746	11,398	-16,296
Income tax expense	-	-	-	100
Income tax expense	45	181	-47	56
Net loss and comprehensive loss	-18,856	-11,927	11,445	-16,352

Basic EPS	-2.93	0.045	0.12	-0.17
Diluted EPS	-2.93	0.044	0.11	-0.17
Basic Average Shares	6,434,000	-262,280,000	96,245,000	95,970,000
Diluted Average Shares	6,434,000	-272,549,000	106,514,000	95,970,000

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.